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Determination of protein crystal structures requires that the phases are derived
independently of the observed measurement of diffraction intensities. Many
techniques have been developed to obtain phases, including heavy-atom
substitution, molecular replacement and substitution during protein expression
of the amino acid methionine with selenomethionine. Although the use of
selenium-containing methionine has transformed the experimental determina-
tion of phases it is not always possible, either because the variant protein cannot
be produced or does not crystallize. Phasing of structures by measuring the
anomalous diffraction from S atoms could in theory be almost universal since
almost all proteins contain methionine or cysteine. Indeed, many structures
have been solved by the so-called native sulfur single-wavelength anomalous
diffraction (S-SAD) phasing method. However, the anomalous effect is weak at
the wavelengths where data are normally recorded (between 1 and 2 A˚) and
this limits the potential of this method to well diffracting crystals. Longer
wavelengths increase the strength of the anomalous signal but at the cost of
increasing air absorption and scatter, which degrade the precision of the
anomalous measurement, consequently hindering phase determination. A new
instrument, the long-wavelength beamline I23 at Diamond Light Source, was
designed to work at significantly longer wavelengths compared with standard
synchrotron beamlines in order to open up the native S-SAD method to projects
of increasing complexity. Here, the first novel structure, that of the oxidase
domain involved in the production of the natural product patellamide, solved on
this beamline is reported using data collected to a resolution of 3.15 A˚ at a
wavelength of 3.1 A˚. The oxidase is an example of a protein that does not
crystallize as the selenium variant and for which no suitable homology model
for molecular replacement was available. Initial attempts collecting anomalous
diffraction data for native sulfur phasing on a standard macromolecular
crystallography beamline using a wavelength of 1.77 A˚ did not yield a structure.
The new beamline thus has the potential to facilitate structure determination by
native S-SAD phasing for what would previously have been regarded as very
challenging cases with modestly diffracting crystals and low sulfur content.
1. Introduction
The majority of structures from macromolecular crystals
can nowadays be solved by molecular replacement.
However, in the absence of suitable homology models,
experimental phasing is the method of choice to overcome the
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crystallographic phase problem. This method requires
measurements of the small anomalous differences arising
when tuning the wavelength of the X-rays towards the
absorption edges of atoms bound to the structures. The most
successful label used is selenium by substituting the amino
acid methionine by selenomethionine. However, this tech-
nique is not universal as it is not compatible with all expression
systems and, even if the labelled protein can be produced,
crystallization fails in some cases.
The native sulfur single-wavelength anomalous diffraction
(S-SAD) method can overcome this by exploiting the intrinsic
anomalous signal from sulfur. Over the past years, several
studies have demonstrated the applicability of this method to
problems of increasing complexity (Liu et al., 2012; Weinert et
al., 2015; El Omari et al., 2014; Rose et al., 2015). On standard
experimental setups, typically optimized for wavelengths
around the selenium K edge ( = 0.97 A˚) and operated in air,
S-SAD experiments are performed in the wavelength range
1.7–2.3 A˚. The wavelength choice is limited mainly by the
increased background noise from air scattering and the
reduced signal from air absorption, as well as the size of the
detector, given that the diffraction angles needed to measure
data at constant resolution increase with the wavelength. To
measure the small anomalous signals, high-redundancy data
from well diffracting crystals or merging data from multiple
isomorphous crystals are needed. The sulfur K edge is at
 = 4.96 A˚ and the anomalous signal increases approximately
with the cube of the wavelength as it moves towards the
edge. The new long-wavelength MX beamline I23 at
Diamond Light Source has been designed to provide an
optimized environment for native SAD experiments, enabling
experiments at longer wavelengths to increase the anomalous
signal with minimal noise (Wagner et al., 2016).
Cyanobactins are a family of ribosomally synthesized and
post-translationally modified peptides (RiPPs; Arnison et al.,
2013) from cyanobacteria. Each product is tailored using a
selected set of enzymes to produce linear or macrocyclic
peptides (Sivonen et al., 2010). The patellamide pathway
(Schmidt et al., 2005) is the best characterized pathway. The
first step in patellamide biosynthesis is the ATP-dependent
dehydration of cysteine, threonine and serine by the hetero-
cyclase PatD to form thiazoline, methyl oxazoline and
oxazoline, respectively (Fig. 1). Following this cyclode-
hydration, the N-terminus is cleaved off by the PatA protease
domain and subsequently macrocyclized by the macrocyclase
domain of PatG. Structures have been determined for the
heterocyclase (cyclic dehydratase; Koehnke et al., 2013, 2015),
protease (Houssen et al., 2012; Agarwal et al., 2012), prenyl-
transferase (Bent et al., 2013), a conserved domain of
unknown function (Mann et al., 2014) and macrocyclase
(Koehnke et al., 2012; Agarwal et al., 2012) proteins from
various cyanobactin pathways. The only enzyme function
remaining to be solved in the patellamide cluster is
that of the FMN-dependent cyanobactin azoline oxidase.
The oxidase converts thiazolines to thiazoles, with some
enzymes also capable of the oxidation of oxazolines to
oxazoles (Fig. 1, Table 1). The oxidase domain is conserved
in patellamide-like pathways either as a fused domain to
the G protein or as a standalone protein (Martins &
Vasconcelos, 2015); the exception to this is the trunkamide
pathway, in which the final compounds are not
oxidized.
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Figure 1
Synthesis schematic of the two-step process to form thiazoles and oxazoles in cyanobactins. The initial step is the ATP-dependent PatD reaction to the
form thiazolines and oxazoline, followed by FMN-dependent oxidation by PatGox to yield thiazoles. Note that in related pathways the oxazolines are
also oxidized to oxazole rings.
Table 1
PatGox and homologues.
Enzyme Fused/standalone Natural products contain Organism/biosynthetic pathway
PatGox Fused, part of PatG Thiazoles, oxazolines Prochloron sp./patellamides
ThcOx Standalone Thiazoles, thiazolines, oxazolines Cyanothece PCC 7425/cyanothecamides
ThcOx2 Standalone Thiazoles, thiazolines, oxazolines Cyanothece PCC 7822
TriOx Standalone Thiazoles Trichodesmium erythraeum ISM101/trichamide
McaGox Fused, part of McaG Thiazoles, oxazoles Microcystis aeruginosa NIES-298/microcyclamide
ArtGox Fused, part of ArtG Thiaozles Arthrospira spirulina/arthrospiramides
LynGox Fused, part of LynG Thiazoles Lyngbya aestuarii CCY9616/aestuaramides
TenGox Fused, part of TenG Thiazoles, oxazoles Nostoc spongiaeforme var. tenue/tenuecyclamide
Here, we present ThcOx, the first novel structure to be
solved by in-vacuum long-wavelength macromolecular
crystallography on beamline I23 at Diamond Light Source
(Wagner et al., 2016), and its subsequent high-resolution
structure solved by molecular replacement.
2. Materials and methods
2.1. Cloning, expression and purification of ThcOx
The ThcOx gene was amplified from gDNA of cultured
Cyanothece sp. PCC 7425 obtained from the Pasteur Culture
Collection of Cyanobacteria (Paris) and subcloned with an
N-terminal Tobacco etch virus (TEV) protease-cleavable His6
tag followed by a four-glycine linker into a pJexpress 401
vector from DNA2.0 (Table 2). It was expressed in Escherichia
coli BL21 (DE3) cells grown on autoinduction medium
supplemented with 50 mM riboflavin for 48 h at 20C. Cell
pellets were resuspended in lysis buffer plus EDTA-free
protease-inhibitor tablets (Roche) and DNase at 0.4 mg per
gram of wet cell pellet. The resuspension was lysed by passage
through a cell disruptor at 207 MPa (Constant Systems). The
lysate was cleared by centrifugation (40 000g, 4C, 20 min) and
then loaded onto an Ni Sepharose 6 Fast Flow column (GE
Healthcare) equilibrated with lysis buffer [150 mM NaCl,
20 mM Tris–HCl pH 8.0, 20 mM imidazole pH 8.0, 50 mM
flavin mononucleotide (FMN), 3 mM -mercaptoethanol
(BME)]. The column was washed with lysis buffer and ThcOx
was then eluted with elution buffer (150 mM NaCl, 20 mM
Tris–HCl pH 8.0, 250 mM imidazole pH 8.0, 50 mM FMN,
3 mM BME). The protein was then passed over a desalting
column (16/10 Desalting, GE Healthcare) back into the lysis
buffer. TEV protease was added at a mass ratio of 1:10 and the
protein was digested for 2 h at 20C to remove the His6 tag.
The sample was then loaded onto a second nickel column in
lysis buffer and directly onto an ion-exchange column (HiTrap
Q Sepharose FF, GE Healthcare) and eluted with a 0.15–1M
NaCl gradient. The peak fraction was then concentrated to
7.5 ml (Vivaspin concentrators, 30 kDa molecular-weight
cutoff) and applied onto a Superdex 200 gel-filtration column
(GE Healthcare) equilibrated with gel-filtration buffer
(150 mM NaCl, 10 mM HEPES pH 7.4, 1 mM TCEP). The
lack of FMN in the gel-filtration buffer combined with the
elution fraction remaining yellow in colour confirmed that
FMN was indeed bound to the protein. The protein was
concentrated to 4 mg ml1 for crystallography. The purity of
the protein was confirmed by SDS–PAGE analysis and its
identity was confirmed by mass spectrometry (MS).
2.2. Crystallization
ThcOx protein was mixed in a 1:1.1 ratio with the peptide
NILPQQGQPVIR plus an additional 1 mM FMN cofactor
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Table 2
Macromolecule-production information for ThcOx from Cyanothece sp.
PCC 7425.
Source organism Cyanothece sp. PCC 7425 obtained from
the Pasteur Culture Collection of
Cyanobacteria (Paris)
DNA source gDNA extracted from cultured Cyanothece
sp. PCC 7425 on BG-11 medium with
12 h light/12 h dark cycles. Subcultures
on fresh media were prepared after four
weeks incubation.
Expression vector pJexpress 401 (DNA2.0)
Expression host E. coli BL21 (DE3)
Complete amino-acid sequence
of the construct produced†
MHHHHHHENLYFQ\GGGGMLDLFTLSFSPDLSIA-
SEAEQLTLQSKDDRLILEHPQPGLRTALEQLK-
QGNLTLAQLTELVSEQDGVEAGITFASELEKL-
VDLGWICHSVLPLITAIPIAKDYELNVPDSSW-
QTTAIALSRFAFLHQDLQQLVLESPRSKSKLV-
ILDWRVGAVIAKLAQSDRGFIFATSADSLLAD-
LSLELEELKRLFALLIATQMMDLEPEDETITQ-
WKFHNLLFHHYTRLGRLDNSRKLNLPVFEHRD-
RYPYVKPVISTQAIPLVKPDLTALATTDMTLT-
EAIETRRSIREYSDQPITLAQLGEFLYRCARV-
KAVYTLPEDPMQVGESTTRPYPSGGALYELEI-
YPLVHQCGDLAAGLYHYQPLSHTLHPVADWTP-
EVESLVYDAWRATGQQSIPQIVLIITARFGRL-
FWKYHDIAYSLILKHVGVLYQTFYLVATAMQL-
APSAIGAGNTTKFCQIAGLNPDEEASVGEFSL-
GAAKPQQQS
† The Tobacco etch virus (TEV) protease cleavage point is marked \.
Figure 2
(a) Crystals of ThcOx in complex with the peptide substrate NILPQQGQPVIR. (b) X-ray diffraction pattern of the high-resolution data collected on
beamline I02. (c) Enlarged view of the diffraction data.
and incubated overnight at 273 K prior to setting up crystal-
lization trials. Initial crystallization screening was performed
by sitting-drop vapour diffusion in a 96-well Intelli-Plate
(300 nl protein mixture plus 150 nl reservoir solution) using
a Gryphon robot (Art Robbins; http://www.artrobbins.com/).
The only crystals produced from a wide range of screening
trials were found in condition No. 16 from Wizard Classic
Screen 2 (1.0M sodium citrate, 0.1M CHES pH 9.5) at 293 K.
These crystals were subsequently optimized in Linbro
hanging-drop plates using a drop volume of 2.5 ml + 1.5 ml over
a well of 0.5 ml, with the best crystals found in a condition
consisting of 1.0M sodium citrate, 0.1M CHES pH 7.75 at
293 K (Table 3, Fig. 2a).
2.3. Data collection, processing and phasing
The best crystals of ThcOx were cryoprotected in paraffin
oil and either flash-cooled directly at the synchrotron or
cooled and shipped to the synchrotron. The crystals showed a
high level of non-isomorphism and diffracted to between 4.0
and 2.65 A˚ resolution (Figs. 2b and 2c). In order to phase the
protein structure by molecular replacement, several failed
attempts were made using such proteins as putative nitro-
reductases from Anabaena variabilis (PDB entry 3eo7) and
Ralstonia eutropha (PDB entry 3hj9), both of which were
deposited by the Joint Center for Structural Genomics
(JCSG). We were consistently unable to crystallize a seleno-
methionine variant of the protein under either the native or
alternative crystallization conditions. A range of heavy-atom
soaks were prepared including sodium bromide, lead(II)
acetate, potassium tetrabromoplatinate(II), sodium iodide
and potassium iodide, but none of these were successful in
obtaining phases. The ThcOx protein contains a total of ten S
atoms after removal of the His6 tag (Table 2). With a total of
477 amino-acid residues, the Bijvoet ratio at a wavelength of
2.0 A˚ is 0.98%. Our attempts to solve the structure by S-SAD
phasing with in-house data collected at a wavelength of 1.54 A˚
or on beamline I02 at Diamond Light Source using data
collected at a wavelength of 1.77 A˚ both failed owing to the
low anomalous signal at those wavelengths.
We therefore used the new long-wavelength in-vacuum
beamline I23 with its custom detector to investigate the use
of longer wavelengths for phasing. A wavelength of 3.1 A˚
appeared to be a good compromise between the increase in
the anomalous signal and the decrease in data quality owing to
the greater sample absorption at longer wavelengths. At this
wavelength the Bijvoet ratio is 2.1%, which is more than 2.5
times the value at a wavelength of 1.77 A˚. Owing to the large
crystal-to-crystal variability, 48 crystals had to be transferred
into the beamline vacuum end station before a crystal of
suitable quality could be found. The best crystal diffracted to a
resolution limit of 3.15 A˚. Data were collected with the large
in-vacuum PILATUS 12M detector (Dectris, Switzerland) at a
wavelength of 3.1 A˚ with 0.1 oscillations and 0.1 s exposure
time. A total of 4000 images were measured in inverse-beam
mode with wedge sizes of 20 and were subsequently
processed and scaled with XDS/XSCALE (Kabsch, 2010).
No additional absorption correction was performed. The
substructure was determined with SHELXD (Sheldrick, 2010)
with a success rate of one hit in 1000 trials using a resolution
cutoff of 4.2 A˚ when searching for 18 sites. Using this
substructure, AutoSol (Terwilliger et al., 2009) found non-
crystallographic symmetry, and after density modification
automatic model building placed about 20% of the amino-acid
residues in an electron-density map of sufficient quality to
allow manual model building. The accuracy of the anomalous
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Figure 3
The phased anomalous difference (F+  F) map shows the accuracy of
the anomalous difference measurements collected on beamline I23 using
a wavelength of 3.1 A˚. The map is contoured around the sulfur-containing
residues (a) methionine and (b) cysteine at 3.5. The phases were
calculated from a molecular-replacement solution using the final (high-
resolution) structure as the search model. (Image from PyMOL.)
Table 3
Crystallization.
Method Hanging-drop vapour diffusion
Plate type Linbro 24-well
Temperature (K) 293
Protein concentration 4 mg ml1 plus peptide (1:1.1)
(pre-loaded with FMN)
Buffer composition of protein
solution
150 mM NaCl, 10 mM HEPES pH 7.4,
1 mM TCEP
Composition of reservoir solution 1.0M sodium citrate, 0.1M CHES
pH 7.75
Volume and ratio of drop 2.5 ml + 1.5 ml
Volume of reservoir (ml) 0.5
measurements can be seen in a phased anomalous difference
map, which shows strong peaks for the S atoms (Fig. 3).
This initial model was refined and then used as a search
model for molecular replacement to solve a previous data set
of higher resolution collected on beamline I02 at Diamond
Light Source. The high-resolution data were processed and
scaled in xia2 (Winter, 2010) using XDS (Kabsch, 2010) and
SCALA (Evans, 2006). The structure was determined using
Phaser (McCoy et al., 2007) as part of the CCP4 suite (Winn et
al., 2011). All data-collection statistics can be found in Table 4.
2.4. Refinement
The high-resolution model was refined by iterative cycles
of manual rebuilding using Coot (Emsley et al., 2010) and
refinement using REFMAC5 (Murshudov et al., 2011) in the
CCP4 suite (Winn et al., 2011). TLS restraints were calculated
using the TLSMD server (Painter & Merritt, 2006) and were
used in refinement (Winn et al., 2001). Final refinement
statistics can be found in Table 5. The structure was validated
usingMolProbity (Chen et al., 2010) and the coordinates were
deposited in the Protein Data Bank (PDB entry 5lq4). The
anomalous data have also been deposited.
3. Results
The protein crystals belonged to space group P412121, with two
molecules found in the asymmetric unit. Simple phase exten-
sion from the long-wavelength data used for phasing was not
possible owing to non-isomorphism between the two crystals.
The c axis is more than 10% larger in the long-wavelength
data, and the unit-cell volume is about 15% larger compared
with the data obtained from the crystal which diffracted to the
highest resolution. Hence, molecular replacement was needed
to phase the high-resolution data. This crystal-to-crystal
variability was typical. The structure is composed of a novel
domain and an FMN nitroreductase domain. Each molecule in
the asymmetric unit consists of 16 -helices and 17 -sheets
(Fig. 4; structural figures were created using PyMOL v.1.5.0.4
from Schro¨dinger). The final structure contains residues 3–222
and 233–469 in chain A and 1–222 and 231–473 in chain B. In
both monomers, the missing residues are located between
-helices 7 and 8 (the linker between the two domains) and
at the N- and C-termini. These residues are presumed to be
disordered in the structure. There are four cysteine residues
per molecule, none of which form disulfide bonds.
PISA (Krissinel & Henrick, 2007; Krissinel, 2010) analysis
infers that the dimer is biologically relevant, with each
research papers
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Figure 4
Cartoon representation of ThcOx highlighting the two molecules (green
and cyan) in the asymmetric unit. (Image from PyMOL.)
Table 4
Data collection and processing.
Values in parentheses are for the outer shell.
Diffraction source
Diamond Light
Source beamline I23
Diamond Light
Source beamline I02
Wavelength (A˚) 3.096 1.771
Temperature (K) 50† 100
Detector PILATUS 12M PILATUS 6M
Space group P41212 P41212
a, b, c (A˚) 111.4, 111.4, 217.6 109.3, 109.3, 195.4
, ,  () 90, 90, 90 90, 90, 90
Resolution range (A˚) 217.55–3.15
(3.37–3.15)
72.84–2.65
(2.72–2.65)
Total No. of reflections 575020 (86233) 285753 (21726)
No. of unique reflections 22295 (3452) 35204 (2542)
Completeness (%) 91.6 (80.6) 100.0 (99.6)
Anomalous completeness (%) 92.1 (81.4) 100.0 (99.6)
Multiplicity 25.8 (25.0) 8.1 (8.5)
hI/(I)i 28.8 (2.3) 17.9 (2.7)
Rmeas 0.077 (1.617) 0.089 (0.890)
Overall B factor from
Wilson plot (A˚2)
121 60
† An accurate temperature calibration is still outstanding; this value is based on a
temperature of 44 K at the goniometer head, assuming a temperature rise of around 6 K
through the sample mount.
Table 5
Structure solution and refinement.
Values in parentheses are for the outer shell.
Resolution range (A˚) 72.83–2.65
Completeness (%) 99.9
No. of reflections, working set 33383
No. of reflections, test set 1751
Final Rcryst 0.197
Final Rfree 0.228
No. of non-H atoms
Protein 7289
Ligand 62
Water 4
R.m.s. deviations
Bonds (A˚) 0.008
Angles () 1.29
Average B factors (A˚2)
Protein 76
Ligand (FMN) 48
Water 63
Ramachandran plot
Most favoured (%) 94.5
Allowed (%) 99.1
molecule containing a single FMN. The N-terminal domain
contains a portion (residues 7–86) which, by visual analysis,
supported by Phyre2 (Kelley & Sternberg, 2009), possesses
the same fold as the leader binding domain of TruD (Koehnke
et al., 2013), the so-called ‘peptide-clamp domain’. These
domains are common in the RiPP family (Melby et al., 2014),
and its orientation here suggests a possible role in function.
The remaining residues in domain 1 (87–194) form a second
peptide-clamp domain, but its binding site is buried by an
interaction with the other clamp domain and thus it is unlikely
to be active.
The C-terminal domain (residues 323–469) contains the
FMN molecule and has a high degree of homology (r.m.s.d. =
1.45 A˚) to the putative nitroreductase from A. variabilis
(PDB entry 3eo7; residues 97–245; Fig. 5). Crystals were only
observed when co-crystallized in the presence of the peptide
NILPQQGQPVIR. The peptide was included as there was
evidence that it may bind to the oxidase; however, there was
no evidence of any density for the peptide. We have attempted
to achieve a complex structure with substrate bound at the
catalytic site but have so far been unsuccessful.
4. Discussion
We have reported the first structure of an oxidase protein
from a cyanobactin pathway. The structure was determined by
native S-SAD phasing on the new I23 beamline at Diamond
Light Source. A wavelength of 3.10 A˚ was used to measure a
sufficiently large anomalous signal to experimentally phase
the structure of ThcOx from a crystal which diffracted to
3.15 A˚ resolution with useful anomalous data extending to
only 4.2 A˚ resolution. These resolution limits would tradi-
tionally be unfavourable for phase determination by native
S-SAD, particularly given the large size of the asymmetric unit
(a dimer of 954 residues in total) with relatively few S atoms.
Furthermore, the inability to extend the phases to a higher
resolution data set, caused by non-isomorphism, required that
the initial phases at 3.15 A˚ resolution had to be of sufficient
quality to allow model building. Thus, ThcOx represented a
particularly challenging test for the I23 beamline and the
successful structure determination validates its performance.
This structure determination demonstrates the great
potential of the novel in-vacuum long-wavelength MX
beamline I23. The combination of the in-vacuum sample
environment with the large semi-cylindrical PILATUS 12M
pixel hybrid detector allows very accurate measurements with
minimal background, giving very high signal-to-noise ratios in
a wavelength range typically not accessible at standard MX
beamlines. This new beamline should significantly extend the
range of protein crystals that are amenable to native S-SAD
structure determination.
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